Hotaling Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Hotaling Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.11M	Buy	+1,539	New	+$1.14M	0.5%	66

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hotaling Investment Management's REGN Position: Q4 2022 in Review

Hotaling Investment Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2022: 1,539 shares worth $1.11M. The stake represents 0.5% of the portfolio and ranks #66 among its holdings.

1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Hotaling Investment Management held 1,539 shares of Regeneron Pharmaceuticals worth $1.11M as of Q4 2022.
Regeneron Pharmaceuticals was a new Hotaling Investment Management position in Q4 2022.
Regeneron Pharmaceuticals made up 0.5% of Hotaling Investment Management's portfolio in Q4 2022, its #66 holding.
1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Hotaling Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.